evamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitaemia

niversity of Oxford (United Kingdom)0 个研究点目标入组 60 人开始时间: 2006年5月24日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•Current information as of 29/07/2010:
•1. The patient or attending relative, able and willing to give informed consent. The proposed consent form and information sheets are attached and will be translated into the local language.
•2. Severe falciparum malaria
•3. Peripheral blood parasitaemia more than or equal to 2%
•4. Patients aged 16 to 65 years old, both genders
•5. No contraindications to levamisole, or artesunate therapy, such as documented allergies to either of the drugs
•Initial information at time of registration:
•1. The patient or attending relative, able and willing to give informed consent. The proposed consent form and information sheets are attached and will be translated into the local language.
•2. Severe falciparum malaria
•3. Peripheral blood parasitaemia more than or equal to 5%
•4. Patients aged 16 to 65 years old, both genders
•5. No contraindications to levamisole, or artesunate therapy, such as documented allergies to either of the drugs

•Current information as of 29/07/2010:
•1. Patient or relatives unable or unwilling to give informed consent
•2. More than one dose of previous antimalarial treatment within one week of admission
•3. Pregnancy or breastfeeding
•Initial information at time of registration:
•1. Patient or relatives unable or unwilling to give informed consent
•2. Previous antimalarial treatment within one week of admission
•3. Pregnancy

发起方

niversity of Oxford (United Kingdom)